Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 8:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Skin Manifestations Clear all
Active, not recruiting Phase 3 Interventional

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

NCT05653219
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Ianalumab, Eltrombopag, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Yuma, Arizona • Aurora, Colorado • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 26, 2026, 8:36 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women

NCT03446781
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy (Cellulite)
Interventions
EN3835, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
25
States / cities
Glendale, Arizona • North Little Rock, Arkansas • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 26, 2026, 8:36 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study

NCT07245667
View directory record Official record
Conditions
Tinea Pedis
Interventions
1% Tolnaftate Stick Formula A, 1% Tolnaftate Stick Formula B, 1% Tolnaftate Stick Formula C
Drug
Lead sponsor
Propedix, Inc.
Industry
Eligibility
16 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Framingham, Massachusetts • Milford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 26, 2026, 8:36 PM EDT
Completed Phase 3 Interventional Results available

Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

NCT03721172
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
43
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 26, 2026, 8:36 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)

NCT00411801
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
Uniplas, Cryosupernatant plasma
Biological
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Centreville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Sep 26, 2026, 8:36 PM EDT
Completed Phase 2 Interventional Results available

Tofacitinib for Immune Skin Conditions in Down Syndrome

NCT04246372
View directory record Official record
Conditions
Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa, Vitiligo, Psoriasis
Interventions
Tofacitinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 50 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 26, 2026, 8:36 PM EDT
Completed No phase listed Observational

Association of Platelet Parameters With Bleeding Severity in Children With ITP

NCT03810352
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Months to 20 Years
Enrollment
95 participants
Timeline
2019 – 2023
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 26, 2026, 8:36 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)

NCT05632926
View directory record Official record
Conditions
Cellulite
Interventions
40 mg CBL-514, 60 mg CBL-514, 80 mg CBL-514
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
Encino, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 26, 2026, 8:36 PM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

NCT03281538
View directory record Official record
Conditions
Uremic Pruritus
Interventions
CR845
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
26
States / cities
Chula Vista, California • El Centro, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 26, 2026, 8:36 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Partners in Children's Health (CSN): A Randomized Trial of an Attachment Based Intervention

NCT06002685
View directory record Official record
Conditions
Respiratory Disease, Inflammation, Insufficient Sleep, Digestive Disease, Skin Conditions, Body Mass Index, Infections, Allergies, Congestion, Antibiotic Use, Overweight and Obesity
Interventions
Attachment and Biobehavioral Catch-Up, Home-Based Book-of-the-Week
Behavioral · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
8 Months to 12 Months
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 26, 2026, 8:36 PM EDT
Completed Phase 3 Interventional Results available

Preoperative Acetaminophen and Carbohydrate Loading

NCT03131713
View directory record Official record
Conditions
Non-melanoma Skin Cancer
Interventions
Acetaminophen
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2019 · Synced Sep 26, 2026, 8:36 PM EDT
Terminated Phase 2 Interventional Results available

DDAVP in the Reduction of Post-operative Ecchymosis in Rhinoplasty

NCT01982760
View directory record Official record
Conditions
Postoperative Ecchymosis
Interventions
DDAVP
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Lyndhurst, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Sep 26, 2026, 8:36 PM EDT
Not listed Not applicable Interventional

Evaluation of a Novel Amino Acid Based Moisturizing Cream as Part of the Daily Standard Skincare Regimen Recommended During Radiation Therapy

NCT06016361
View directory record Official record
Conditions
Erythema, Radiation Therapy, Secondary Skin Reactions
Interventions
VS-200Cr, Standard of care
Other
Lead sponsor
Entrinsic Bioscience Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 26, 2026, 8:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment for Improvement of Cellulite Appearance Using Form Applicator

NCT05882721
View directory record Official record
Conditions
Cellulite
Interventions
Sofwave
Device
Lead sponsor
Sofwave Medical LTD
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
5
States / cities
Sacramento, California • Hackensack, New Jersey • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 26, 2026, 8:36 PM EDT
Recruiting Phase 3 Interventional

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

NCT07059000
View directory record Official record
Conditions
Chronic Primary Immune Thrombocytopenia (ITP)
Interventions
Kedrion IVIG 10%
Biological
Lead sponsor
Kedrion S.p.A.
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Shirley, New York • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 26, 2026, 8:36 PM EDT
Terminated Not applicable Interventional

The CEASE Study: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer

NCT01351844
View directory record Official record
Conditions
Breast Cancer, Arthralgia
Interventions
Education and exercise intervention, Education and General Exercise
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Sep 26, 2026, 8:36 PM EDT
Completed Phase 2 Interventional

Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris

NCT03322137
View directory record Official record
Conditions
Pruritus, Psoriasis Vulgaris
Interventions
SNA-120, Vehicle
Drug
Lead sponsor
Sienna Biopharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
38
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Sep 26, 2026, 8:36 PM EDT
Terminated Phase 4 Interventional Results available

IN Ketamine vs IN Midazolam and Fentanyl for Laceration Repair

NCT03528512
View directory record Official record
Conditions
Laceration of Skin
Interventions
Ketamine, Midazolam and fentanyl
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
6 Months to 10 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Sep 26, 2026, 8:36 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the Candela 1064nm:Nd:YAG Laser for Skin Tightening

NCT00585715
View directory record Official record
Conditions
Localized Lipodystrophy
Interventions
1064 nm Nd:YAG laser
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
40 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Sep 26, 2026, 8:36 PM EDT
Completed No phase listed Observational

Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer

NCT00303914
View directory record Official record
Conditions
Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer, Pain, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
assessment of therapy complications, cognitive assessment, psychosocial assessment and care
Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
2,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
32
States / cities
Chicago, Illinois • Evanston, Illinois • Elkhart, Indiana + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 26, 2026, 8:36 PM EDT
Completed Phase 4 Interventional

Prevention of Post-Mastectomy Breast Pain Using Ambulatory Continuous Paravertebral Blocks

NCT01231204
View directory record Official record
Conditions
Paravertebral Catheter Insertion, Mastectomy, Breast Cancer
Interventions
Placebo (normal saline) Continuous Infusion, Ropivicaine 0.4% Continuous Infusion
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2016 · Synced Sep 26, 2026, 8:36 PM EDT
Active, not recruiting No phase listed Observational

Chronic Pain in Rheumatoid Arthritis

NCT05038553
View directory record Official record
Conditions
Arthritis, Rheumatoid, Pain
Interventions
No intervention
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Denver, Colorado • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 26, 2026, 8:36 PM EDT
Completed Phase 1Phase 2 Interventional

RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)

NCT04571970
View directory record Official record
Conditions
Mucopolysaccharidosis Type II (MPS II)
Interventions
RGX-121
Genetic
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
5 Years to 17 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 26, 2026, 8:36 PM EDT
Completed No phase listed Observational

Reproductive Health in Men and Women With Vasculitis

NCT02176070
View directory record Official record
Conditions
Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Behcet's Disease, Kawasaki Disease, Henoch-schoenlein Purpura, Vasculitis, Central Nervous System, Drug-induced Necrotizing Vasculitis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Sep 26, 2026, 8:36 PM EDT